Drugmaker Shire offers to buy Baxalta for US$30b
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
London
IRISH drugmaker Shire said on Tuesday that it had offered to buy the biopharmaceutical company Baxalta in an all-stock deal worth about US$30 billion.
Shire said on Tuesday that it had approached Baxalta in early July about a potential combination, but Baxalta concluded, following a written proposal on July 31, not to proceed with discussions.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
